Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.714 EUR -2.17% Market Closed
Market Cap: 158m EUR

Relative Value

The Relative Value of one IPH stock under the Base Case scenario is 4.673 EUR. Compared to the current market price of 1.714 EUR, Innate Pharma SA is Undervalued by 63%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IPH Relative Value
Base Case
4.673 EUR
Undervaluation 63%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
22
vs Industry
56
Median 3Y
5.7
Median 5Y
6.3
Industry
7.1
Forward
2.5
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-5.5
Industry
23
Forward
19.3
vs History
vs Industry
Median 3Y
-9.1
Median 5Y
-7.5
Industry
19.4
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-7.7
Industry
23.1
vs History
9
vs Industry
18
Median 3Y
4.6
Median 5Y
3.5
Industry
2.6
vs History
20
vs Industry
49
Median 3Y
5.7
Median 5Y
5.5
Industry
7.5
Forward
2.4
vs History
vs Industry
51
Median 3Y
5.2
Median 5Y
5.2
Industry
9.4
vs History
vs Industry
12
Median 3Y
-4.9
Median 5Y
-4.7
Industry
4.4
Forward
14.7
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-4.7
Industry
4.5
Forward
-17.3
vs History
vs Industry
Median 3Y
-8.4
Median 5Y
-7.2
Industry
5.2
vs History
vs Industry
Median 3Y
-8
Median 5Y
-7.2
Industry
3.7
vs History
9
vs Industry
35
Median 3Y
3.3
Median 5Y
2.7
Industry
4.8

Multiples Across Competitors

IPH Competitors Multiples
Innate Pharma SA Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Innate Pharma SA
PAR:IPH
158m EUR 12.5 -3.2 -3 -2.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 258 273 -162 824.5 -197 720.9 -195 464.6
US
Abbvie Inc
NYSE:ABBV
338.9B USD 5.9 81.5 15.5 22.9
US
Amgen Inc
NASDAQ:AMGN
159.5B USD 4.7 26.9 14.4 23.8
US
Gilead Sciences Inc
NASDAQ:GILD
137.7B USD 4.8 23.1 10 13.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD 10.6 -118.9 25.3 26.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 056.4 -524.7 -571.4 -556.2
AU
CSL Ltd
ASX:CSL
115.7B AUD 5 27.5 17 21.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56.8B USD 4 12.6 11.2 12.6
US
Seagen Inc
F:SGT
39.3B EUR 19.8 -60.7 -65.5 -59.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40B USD 17 -148.2 -663.5 -332.5
P/E Multiple
Earnings Growth PEG
FR
Innate Pharma SA
PAR:IPH
Average P/E: 34.3
Negative Multiple: -3.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 824.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.5
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.1
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -118.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -524.7 N/A N/A
AU
CSL Ltd
ASX:CSL
27.5
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.6
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -148.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Innate Pharma SA
PAR:IPH
Average EV/EBITDA: 15.6
Negative Multiple: -3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 720.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.3
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -571.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.2
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -663.5 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Innate Pharma SA
PAR:IPH
Average EV/EBIT: 20.1
Negative Multiple: -2.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 464.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.8
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.9
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.3
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.6
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -332.5 N/A N/A